what's new for the patient with er /her2- mbc progressing on cdk 4/6 inhibitor therapy? expert pe...
Published 3 weeks ago • 8 plays • Length 30:44Download video MP4
Download video MP3
Similar videos
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
8:42
hr mbc: treatment after progression on cdk4/6 inhibition
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
10:02
expert perspectives: cdk 4/6 inhibitors for er breast cancer: emerging data and future implications
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
8:07
management of patients progressing on cdk inhibitors
-
20:19
expert discussion on cdk 4/6 inhibition in breast cancer
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
5:34
considerations for treating patients with cdk4/6 inhibitors
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy